Elaine Chen from STAT News - Journalist Profile

	Profile	Recent Articles on Subject
1	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	STAT+: Is Trump’s new order a reprieve for biotech? - 10 days ago Crisis in CRISPR world, RFK Jr.’s promises, and a novel non-opioid pain drug - 16 days ago AstraZeneca offers some reassurance on China challenges - 16 days ago This week in biotech earnings so far - 17 days ago STAT+: High-dose Wegovy leads to substantial weight loss in trial, but falls short of Zepbound - about 1 month ago The most essential and memorable JPM moments, recapped - about 1 month ago STAT+: Jiangsu Hengrui, a preferred China partner for U.S. biotech, hints at more deals - about 1 month ago East Asians under-represented in biopharma leadership - about 2 months ago Can an epilepsy drug do more than reduce seizures? - about 2 months ago STAT+: 3 trends to watch in biotech in 2025 - about 2 months ago A key decision on compounding is expected this week - 2 months ago Gameto says first baby born using new stem-cell tech - 2 months ago The pharma industry’s silence on RFK Jr., and efforts by parents to develop gene therapies for their children - 2 months ago STAT+: Schizophrenia drug AbbVie picked up in $9 billion acquisition fails in key trials - 3 months ago AstraZeneca falls on reports of Chinese probe - 4 months ago STAT+: Novo Nordisk reports continued growth in obesity drug sales - 4 months ago Investors reevaluate this year’s obesity darling - 4 months ago STAT+: With new Wegovy data in hand, Novo Nordisk will file for approval in MASH - 4 months ago Lilly’s earnings surprise, investors mull the election, & a spooky ghost story - 4 months ago STAT+: Eli Lilly weight loss drug shortage underscores deeper issues with FDA oversight - 4 months ago Pfizer’s activist troubles, gene therapy questions, RFK Jr.’s MAHA ambitions - 4 months ago STAT+: Ozempic linked to lower risk of Alzheimer’s diagnosis in observational study - 4 months ago Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - 4 months ago More evidence on GLP-1s and opioid addiction - 4 months ago Biden’s health care AI czar, a new obesity company, and its dealmaking CEO - 5 months ago Can GLP-1 drugs help with type 1 diabetes? - 5 months ago A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids - 5 months ago Moderna cuts spending, and Sarepta’s ‘curse’ on Califf - 5 months ago STAT+: Gilead’s twice-yearly antiviral protects against HIV infection in second large trial - 5 months ago Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 6 months ago STAT+: Can amylin drugs best Wegovy and Zepbound? Companies bet on next big obesity target - 6 months ago BioMarin’s big day today - 6 months ago Listen: BioMarin’s executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion’s AI bona fides - 6 months ago Does Ozempic increase the risk of suicidal thoughts? - 6 months ago STAT+: Lilly’s Zepbound slashed risk of developing diabetes - 6 months ago STAT+: What to know about Alnylam’s upcoming readout on its heart drug - 6 months ago Listen: Drug pricing drops & psychedelics under fire - 6 months ago Moderna is still in a Covid hangover - 7 months ago Listen: The long journey to make malaria vaccines, and Sarepta’s ties with patient advocates - 7 months ago venBio raises $528 million for its fifth fund - 7 months ago Merck lays off workers amid rough pharma job market - 7 months ago Contradictory coverage decisions in North Carolina - 7 months ago STAT+: Gilead’s chief medical officer to leave as R&D efforts stall - 7 months ago It’s happy hour (for now) for Alnylam - 7 months ago As GLP-1 sales surge, insulin users fear Novo Nordisk and Eli Lilly will move on without them - 7 months ago Listen: Biotech layoffs, founder-focused VC, & a big pharma exit - 8 months ago Can you get satiety with GLP-1s without the nausea? - 8 months ago STAT+: Pfizer says it will advance once-daily GLP-1 pill after all - 8 months ago STAT+: Eli Lilly to acquire Morphic for $3.2 billion - 8 months ago STAT+: Supreme Court’s gutting of Chevron doctrine could mean headaches for drug industry - 8 months ago
2	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	Crisis in CRISPR world, RFK Jr.’s promises, and a novel non-opioid pain drug - 16 days ago The pharma industry’s silence on RFK Jr., and efforts by parents to develop gene therapies for their children - 2 months ago Lilly’s earnings surprise, investors mull the election, & a spooky ghost story - 4 months ago Pfizer’s activist troubles, gene therapy questions, RFK Jr.’s MAHA ambitions - 4 months ago Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - 4 months ago Biden’s health care AI czar, a new obesity company, and its dealmaking CEO - 5 months ago A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids - 5 months ago Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 6 months ago Listen: BioMarin’s executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion’s AI bona fides - 6 months ago STAT+: What to know about Alnylam’s upcoming readout on its heart drug - 6 months ago Listen: Drug pricing drops & psychedelics under fire - 6 months ago Listen: The long journey to make malaria vaccines, and Sarepta’s ties with patient advocates - 7 months ago Listen: Biotech layoffs, founder-focused VC, & a big pharma exit - 8 months ago
3	Jason Mast STAT News Writing about science, medicine. ScienceMedicineBusiness	The most essential and memorable JPM moments, recapped - about 1 month ago
4	Angus Chen STAT News Undignified, unfunny journalist. Health, cancer coverage at STAT News. journalismhealthcancer researchSTAT News	The most essential and memorable JPM moments, recapped - about 1 month ago
5	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Jiangsu Hengrui, a preferred China partner for U.S. biotech, hints at more deals - about 1 month ago The pharma industry’s silence on RFK Jr., and efforts by parents to develop gene therapies for their children - 2 months ago Lilly’s earnings surprise, investors mull the election, & a spooky ghost story - 4 months ago Pfizer’s activist troubles, gene therapy questions, RFK Jr.’s MAHA ambitions - 4 months ago Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - 4 months ago Biden’s health care AI czar, a new obesity company, and its dealmaking CEO - 5 months ago A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids - 5 months ago Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 6 months ago STAT+: Can amylin drugs best Wegovy and Zepbound? Companies bet on next big obesity target - 6 months ago Listen: BioMarin’s executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion’s AI bona fides - 6 months ago Listen: Drug pricing drops & psychedelics under fire - 6 months ago Listen: The long journey to make malaria vaccines, and Sarepta’s ties with patient advocates - 7 months ago Listen: Biotech layoffs, founder-focused VC, & a big pharma exit - 8 months ago
6	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: Novo Nordisk reports continued growth in obesity drug sales - 4 months ago STAT+: What to know about Alnylam’s upcoming readout on its heart drug - 6 months ago
7	Lizzy Lawrence STAT News Medical devices reporter at STATnews. Loves news tips. medical reportingnews	STAT+: Eli Lilly weight loss drug shortage underscores deeper issues with FDA oversight - 4 months ago STAT+: Supreme Court’s gutting of Chevron doctrine could mean headaches for drug industry - 8 months ago
8	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Eli Lilly weight loss drug shortage underscores deeper issues with FDA oversight - 4 months ago
9	Matthew Herper STAT News Writes at STAT. Biology's century. Undisclosed biologydatajournalism	STAT+: Pfizer says it will advance once-daily GLP-1 pill after all - 8 months ago
10	John Wilkerson STAT News STAT Washington correspondent. Healthcare Journalism	STAT+: Supreme Court’s gutting of Chevron doctrine could mean headaches for drug industry - 8 months ago